Xiaomeng Chen

Xiaomeng Chen

Auto-generated profile, based on publicly available information

Xiaomeng Chen

Department of Surgery Johns Hopkins University School of Medicine Baltimore Maryland USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2020 in American Journal of Nephrology
Verified
Journal Article
Open access
PDF file
NCNadia M. Chu
Nadia M. Chu
XCXiaomeng Chen
Xiaomeng Chen
SNSilas P. Norman
Silas P. Norman
JFJessica Fitzpatrick
Jessica Fitzpatrick
SSStephen M. Sozio
Stephen M. Sozio
MMMara A. McAdams-DeMarco
Mara A. McAdams-DeMarco
Background: Frailty, originally characterized in community-dwelling older adults, is increasingly being studied and implemented for adult patients with end-stage kidney disease (ESKD) of all ages (>18 years). Frailty prevalence and manifestation are unclear in younger adults (18–64 years) with ESKD; differences likely exist based on whether the patients are treated with hemodialysis (HD) or kidney transplantation (KT). Methods: We leveraged 3 cohorts: 378 adults initiating HD (2008–2012), 4,304 adult KT candidates (2009–2019), and 1,396 KT recipients (2008–2019). The frailty phenotype was measured within 6 months of dialysis initiation, at KT evaluation, and KT admission. Prevalence of frailty and its components was estimated by age (≥65 vs. <65 years). A Wald test for interactions was used to test whether risk factors for frailty differed by age. Results: In all 3 cohorts, frailty prevalence was higher among older than younger adults (HD: 71.4 vs. 47.3%; candidates: 25.4 vs. 18.8%; recipients: 20.8 vs. 14.3%). In all cohorts, older patients were more likely to have slowness and weakness but less likely to report exhaustion. Among candidates, older age (odds ratio [OR] = 1.79, 95% CI: 1.47–2.17), non-Hispanic black race (OR = 1.30, 95% CI: 1.08–1.57), and dialysis type (HD vs. no dialysis: OR = 2.06, 95% CI: 1.61–2.64; peritoneal dialysis vs. no dialysis: OR = 1.78, 95% CI: 1.28–2.48) were associated with frailty prevalence, but sex and Hispanic ethnicity were not. These associations did not differ by age (pinteractions > 0.1). Similar results were observed for recipients and HD patients. Conclusions: Although frailty prevalence increases with age, younger patients have a high burden. Clinicians caring for this vulnerable population should recognize that younger patients may experience frailty and screen all age groups.

1 January 2022 in Surgery
Verified
Journal Article
Closed access
WSWhitney Sutton
Whitney Sutton
XCXiaomeng Chen
Xiaomeng Chen
PPPalak Patel
Palak Patel
SKShkala Karzai
Shkala Karzai
JPJason D. Prescott
Jason D. Prescott
AMAarti Mathur
Aarti Mathur

1 July 2021 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
KTKathryn Taylor
Kathryn Taylor
NCNadia M. Chu
Nadia M. Chu
XCXiaomeng Chen
Xiaomeng Chen
ZSZhan Shi
Zhan Shi
EREileen Rosello
Eileen Rosello
MMMara A. McAdams-DeMarco
Mara A. McAdams-DeMarco
Background and objectives: Patients with kidney failure report a high symptom burden, which likely increases while on dialysis due to physical and mental stressors and decreases after kidney transplantation due to restoration of kidney function. Design, setting, participants, & measurements: We leveraged a two-center prospective study of 1298 kidney transplant candidates and 521 recipients (May 2014 to March 2020). Symptom scores (0–100) at evaluation and admission for transplantation were calculated using the Kidney Disease Quality of Life Short-Form Survey, where lower scores represent greater burden, and burden was categorized as very high: 0.0–71.0; high: 71.1–81.0; medium: 81.1–91.0; and low: 91.1–100.0. We estimated adjusted waitlist mortality risk (competing risks regression), change in symptoms between evaluation and transplantation (n=190), and post-transplantation symptom score trajectories (mixed effects models). Results: At evaluation, candidates reported being moderately to extremely bothered by fatigue (32%), xeroderma (27%), muscle soreness (26%), and pruritus (25%); 16% reported high and 21% reported very high symptom burden. Candidates with very high symptom burden were at greater waitlist mortality risk (adjusted subdistribution hazard ratio, 1.67; 95% confidence interval, 1.06 to 2.62). By transplantation, 34% experienced an increased symptom burden, whereas 42% remained unchanged. The estimated overall symptom score was 82.3 points at transplantation and 90.6 points at 3 months (10% improvement); the score increased 2.75 points per month (95% confidence interval, 2.38 to 3.13) from 0 to 3 months, and plateaued (−0.06 points per month; 95% confidence interval, −0.30 to 0.18) from 3 to 12 months post-transplantation. There were early (first 3 months) improvements in nine of 11 symptoms; pruritus (23% improvement) and fatigue (21% improvement) had the greatest improvements. Conclusions: Among candidates, very high symptom burden was associated with waitlist mortality, but for those surviving and undergoing kidney transplantation, symptoms improved.

8 January 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
XCXiaomeng Chen
Xiaomeng Chen
OSOmid Shafaat
Omid Shafaat
YLYi Liu
Yi Liu
EKElizabeth A. King
Elizabeth A. King
CWClifford Raabe Weiss
Clifford Raabe Weiss
MMMara A. McAdams-DeMarco
Mara A. McAdams-DeMarco
Kidney transplantation (KT) experts did not support the use of subjective unintentional weight loss to measure shrinking in the Physical Frailty Phenotype (PFP); a clinically feasible and predictive measure of shrinking is needed. To test whether unintentional weight loss could be replaced by an assessment of sarcopenia using existing CT scans, we performed a prospective cohort study of adult KT recipients with original PFP (oPFP) measured at admission (12/2008–2/2020). We ascertained sarcopenia by calculating skeletal muscle index from available, clinically obtained CTs within 1-year pre-KT (male<50cm2/m2; female<39cm2/m2) and combined it with the original 4 components to determine new PFP (nPFP) scores. Frailty was classified by frailty score: 0:non-frail;1–2:pre-frail;≥3:frail. Mortality and graft loss hazard ratios (HRs) were estimated using adjusted Cox proportional hazard models. Model discrimination was quantified using Harrell’s C-statistic. Among 1,113 recipients, 18.6% and 17.1% were frail by oPFP and nPFP, respectively. Compared to non-frail recipients, frail patients by either PFP had higher risks of mortality (oPFP HR=1.67,95%CI:1.07–2.62,C=0.710; nPFP HR=1.68,95%CI:1.06–2.66,C=0.710) and graft loss (oPFP HR=1.67,95%CI:1.17–2.40,C=0.631; nPFP HR=1.66,95%CI:1.15–2.40,C=0.634) with similar discriminations. oPFP and nPFP are equally useful in risk prediction for KT recipients; oPFP may aid in screening patients for pre-KT interventions, while nPFP may assist in nuanced clinical decision-making.

18 August 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
NCNadia M. Chu
Nadia M. Chu
SBSunjae Bae
Sunjae Bae
XCXiaomeng Chen
Xiaomeng Chen
JRJessica Ruck
Jessica Ruck
AGAlden L. Gross
Alden L. Gross
MMMara A. McAdams-DeMarco
Mara A. McAdams-DeMarco
Kidney transplant (KT) recipients with delirium, a preventable surgical complication, are likely to reap cognitive benefits from restored kidney function, but may be more vulnerable to longer-term neurotoxic stressors post-KT (i.e., aging, immunosuppression). In this prospective cohort study, we measured delirium (chart-based), global cognitive function (3MS), and executive function (Trail Making Test Part B minus Part A) in 894 recipients (2009-2021) at KT, 1/3/6-months, 1-year, and annually post-KT. Dementia was ascertained using linked Medicare claims. We described repeated measures of cognitive performance (mixed effects model) and quantified dementia risk (Fine & Gray competing risk) by post-KT delirium. Of 894 recipients, 43(4.8%) had post-KT delirium. Delirium was not associated with global cognitive function at KT (difference = -3.2 points, 95%CI: -6.7, 0.4) or trajectories post-KT (0.03 points/month, 95%CI: -0.27, 0.33). Delirium was associated with worse executive function at KT (55.1 s, 95%CI: 25.6, 84.5), greater improvements in executive function 2 years post-KT (1.72 s/month, 95%CI: 0.22, 3.21). Post-KT delirium was associated with over 7-fold greater risk of dementia post-KT (adjusted subdistribution hazard ratio = 7.84, 95%CI: 1.22, 50.40). Transplant centers should be aware of cognitive risks associated with post-KT delirium and implement available preventative interventions to reduce delirium risk.

14 October 2022 in Surgery
Verified
Journal Article
Open access
PCPhilip Crepeau
Philip Crepeau
XCXiaomeng Chen
Xiaomeng Chen
RURhea Udyavar
Rhea Udyavar
LMLilah F. Morris-Wiseman
Lilah F. Morris-Wiseman
DSDorry L. Segev
Dorry L. Segev
AMAarti Mathur
Aarti Mathur
Hyperparathyroidism persists in many patients after kidney transplantation. The purpose of this study was to evaluate the association between post-transplant hyperparathyroidism and kidney transplantation outcomes. We identified 824 participants from a prospective longitudinal cohort of adult patients who underwent kidney transplantation at a single institution between December 2008 and February 2020. Parathyroid hormone levels before and after kidney transplantation were abstracted from medical records. Post-transplant hyperparathyroidism was defined as parathyroid hormone level ≥70 pg/mL 1 year after kidney transplantation. Cox proportional hazards models were used to estimate the adjusted hazard ratios of mortality and death-censored graft loss by post-transplant hyperparathyroidism. Models were adjusted for age, sex, race/ethnicity, college education, parathyroid hormone level before kidney transplantation, cause of kidney failure, and years on dialysis before kidney transplantation. A Wald test for interactions was used to evaluate the risk of death-censored graft loss by age, sex, and race. Of 824 recipients, 60.9% had post-transplant hyperparathyroidism. Compared with non-hyperparathyroidism patients, those with post-transplant hyperparathyroidism were more likely to be Black (47.2% vs 32.6%), undergo dialysis before kidney transplantation (86.9% vs 76.6%), and have a parathyroid hormone level ≥300 pg/mL before kidney transplantation (26.8% vs 9.5%) (all P < .001). Patients with post-transplant hyperparathyroidism had a 1.6-fold higher risk of death-censored graft loss (adjusted hazard ratio = 1.60, 95% confidence interval: 1.02-2.49) compared with those without post-transplant hyperparathyroidism. This risk more than doubled in those with parathyroid hormone ≥300 pg/mL 1 year after kidney transplantation (adjusted hazard ratio = 4.19, 95% confidence interval: 1.95-9.03). The risk of death-censored graft loss did not differ by age, sex, or race (all Pinteraction > .05). There was no association between post-transplant hyperparathyroidism and mortality. The risk of graft loss was significantly higher among patients with post-transplant hyperparathyroidism when compared with patients without post-transplant hyperparathyroidism.